Trial Profile
An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec? (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 22 Mar 2011 New trial record